tradingkey.logo

Ocugen, Inc. Announces Signing Of Binding Term Sheet For The License Of Ocu400 Modifier Gene Therapy For Retinitis Pigmentosa In Korea

ReutersJun 5, 2025 11:22 AM

Ocugen Inc OCGN.O:

  • OCUGEN, INC. ANNOUNCES SIGNING OF BINDING TERM SHEET FOR THE LICENSE OF OCU400 MODIFIER GENE THERAPY FOR RETINITIS PIGMENTOSA IN KOREA

  • OCUGEN INC - TO RECEIVE UP TO $11 MILLION IN UPFRONT FEES

  • OCUGEN INC - SALES MILESTONES OF $150 MILLION OR MORE IN FIRST 10 YEARS OF COMMERCIALIZATION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI